Free Trial

Zevra Therapeutics (ZVRA) Competitors

Zevra Therapeutics logo
$11.56 +0.01 (+0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$11.69 +0.13 (+1.12%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZVRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMY

Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

Zevra Therapeutics vs. Its Competitors

Vericel (NASDAQ:VCEL) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Vericel has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.

35.0% of Zevra Therapeutics shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vericel has a net margin of 1.25% compared to Zevra Therapeutics' net margin of -226.78%. Vericel's return on equity of 1.09% beat Zevra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vericel1.25% 1.09% 0.73%
Zevra Therapeutics -226.78%-201.05%-53.55%

Vericel presently has a consensus price target of $61.14, indicating a potential upside of 47.33%. Zevra Therapeutics has a consensus price target of $23.14, indicating a potential upside of 100.20%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

In the previous week, Zevra Therapeutics had 8 more articles in the media than Vericel. MarketBeat recorded 10 mentions for Zevra Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.73 indicating that Vericel is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vericel
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zevra Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vericel has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$237.22M8.81$10.36M$0.031,383.33
Zevra Therapeutics$23.61M26.77-$105.51M-$1.90-6.08

Summary

Vericel beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVRA vs. The Competition

MetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$631.55M$2.39B$5.51B$8.96B
Dividend YieldN/A1.80%5.25%4.02%
P/E Ratio-6.089.2628.0520.15
Price / Sales26.77771.14438.14127.85
Price / CashN/A161.3437.0657.97
Price / Book15.624.638.125.62
Net Income-$105.51M$31.26M$3.16B$248.50M
7 Day Performance22.85%6.81%4.40%5.54%
1 Month Performance25.79%4.31%4.09%7.52%
1 Year Performance111.14%3.88%34.53%22.06%

Zevra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVRA
Zevra Therapeutics
2.7477 of 5 stars
$11.56
+0.1%
$23.14
+100.2%
+157.2%$631.55M$23.61M-6.0820
VCEL
Vericel
2.9345 of 5 stars
$41.79
+0.8%
$61.14
+46.3%
-14.4%$2.10B$237.22M1,393.30300
AGIO
Agios Pharmaceuticals
4.0684 of 5 stars
$36.06
+2.0%
$58.60
+62.5%
-11.9%$2.09B$36.50M3.21390
CGON
CG Oncology
2.3595 of 5 stars
$26.90
+0.8%
$58.67
+118.1%
-19.0%$2.05B$1.14M-17.8161
KNSA
Kiniksa Pharmaceuticals International
3.4296 of 5 stars
$27.86
+1.5%
$38.80
+39.3%
+37.0%$2.03B$423.24M-111.42220Analyst Upgrade
BEAM
Beam Therapeutics
2.6478 of 5 stars
$20.02
+0.7%
$48.75
+143.5%
-14.9%$2.01B$63.52M0.00510Gap Up
IDYA
IDEAYA Biosciences
3.4092 of 5 stars
$22.09
+0.8%
$53.42
+141.8%
-45.7%$1.94B$7M-6.1580News Coverage
Analyst Forecast
IRON
Disc Medicine
3.1623 of 5 stars
$54.75
+3.0%
$96.70
+76.6%
+11.5%$1.90BN/A0.0030Insider Trade
BLTE
Belite Bio
2.6439 of 5 stars
$59.74
+5.2%
$96.67
+61.8%
+23.7%$1.89BN/A0.0010Analyst Revision
CNTA
Centessa Pharmaceuticals
2.5803 of 5 stars
$14.34
+4.3%
$27.89
+94.6%
+50.3%$1.88B$6.85M0.00200
HRMY
Harmony Biosciences
4.8134 of 5 stars
$32.09
-0.1%
$53.63
+67.1%
+0.6%$1.85B$714.73M12.27200Positive News

Related Companies and Tools


This page (NASDAQ:ZVRA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners